P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
NCT00603642
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
DRUG:
Placebo
DRUG:
AMG 531
Sponsor
Amgen